As of 2025-07-03, the Intrinsic Value of HLS Therapeutics Inc (HLS.TO) is (12.36) CAD. This HLS.TO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 4.80 CAD, the upside of HLS Therapeutics Inc is -357.50%.
The range of the Intrinsic Value is (32.24) - (8.56) CAD
Based on its market price of 4.80 CAD and our intrinsic valuation, HLS Therapeutics Inc (HLS.TO) is overvalued by 357.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (32.24) - (8.56) | (12.36) | -357.5% |
| DCF (Growth 10y) | (7.34) - (23.24) | (9.90) | -306.3% |
| DCF (EBITDA 5y) | (3.00) - (2.98) | (1,688.80) | -123450.0% |
| DCF (EBITDA 10y) | (3.11) - (3.03) | (1,688.80) | -123450.0% |
| Fair Value | -3.89 - -3.89 | -3.89 | -181.03% |
| P/E | (8.15) - (12.59) | (11.88) | -347.5% |
| EV/EBITDA | 4.44 - 6.13 | 5.25 | 9.4% |
| EPV | 24.87 - 29.60 | 27.23 | 467.4% |
| DDM - Stable | (14.02) - (652.61) | (333.31) | -7044.0% |
| DDM - Multi | (12.12) - (438.45) | (23.58) | -591.1% |
| Market Cap (mil) | 151.82 |
| Beta | 1.17 |
| Outstanding shares (mil) | 31.63 |
| Enterprise Value (mil) | 214.76 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.00% |
| Cost of Debt | 7.00% |
| WACC | 6.21% |